Argenica Therapeutics Ltd

AGN · AU · Healthcare / Biotechnology

0.12AUD-0.01 (-7.69%)

Price History

Full chart

Market Stats

Previous Close0.13

Open0.13

Day Range0.12 – 0.13

52-Week Range0.087 – 0.345

Volume243.53K

Market Cap16.70M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.01

Dividend Yield0.00%

Beta0.78

50-Day Avg0.1689

200-Day Avg0.1859

About

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Liz Dallimore B.Sc., M.B.A., Ph.D.
Employees0
Headquarters117 Broadway, Nedlands, WA, Australia, 6009, Australia
Websitehttps://argenica.com.au

Leadership

Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.CEO, MD & Director
Ms. Emma WaldonCFO & Company Secretary · b. 1976
Prof. Bruno Philip MeloniChief Scientific Officer

Financials

Income Statement

Currency: AUD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	250	200	2.50K	1.75M	2.60M	3.21M	-
Growth (%)	-	-20.00%	+1150.00%	+69895.96%	+48.46%	+23.70%	-
Gross Profit	-	296.07K	259.10K	1.75M	2.60M	3.21M	-
Gross Margin	-	148037.50%	10363.92%	100.00%	100.00%	100.00%	-
Operating Expense	-	1.33M	4.35M	8.37M	8.27M	10.90M	-
Operating Income	-383.65K	-1.03M	-4.09M	-6.62M	-5.67M	-7.68M	-7.06M
Operating Margin	-153460.00%	-514713.50%	-163597.20%	-378.59%	-218.30%	-239.05%	-
EBITDA	-383.65K	-1.03M	-4.09M	-4.81M	-1.90M	-7.17M	-7.06M
EBITDA Margin	-153460.00%	-514713.50%	-163597.20%	-275.10%	-73.04%	-223.10%	-
Net Income	-383.40K	-1.03M	-4.09M	-4.82M	-5.48M	-7.17M	-1.37M
Net Income Margin	-153361.20%	-514750.50%	-163630.08%	-275.16%	-210.92%	-223.11%	-
R&D	332.99K	416.05K	2.50M	4.31M	6.02M	8.13M	4.21M
R&D as % of Total Revenue	133194.40%	208023.50%	99842.08%	246.19%	231.60%	253.05%	-
Interest Expense	0	20	822	1.05K	369	503	-
Interest Expense % of Total Revenue	0.00%	10.00%	32.88%	0.06%	0.01%	0.02%	-

Balance Sheet

Currency: AUD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	377.66K	7.27M	9.04M	9.54M	16.38M	11.04M	6.52M
Total Liabilities	359.26K	425.72K	735.91K	1.87M	2.43M	3.80M	614.55K
Total Equity	18.40K	6.85M	8.31M	7.67M	13.95M	7.24M	5.90M
Cash	341.98K	7.14M	8.91M	9.29M	15.91M	10.56M	6.36M
Net Debt	-341.98K	-7.14M	-8.91M	-9.29M	-15.91M	-10.56M	-6.36M

Cash Flow

Currency: AUD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-58.82K	-1.05M	-3.36M	-3.30M	-5.06M	-5.70M	-4.19M
Investing Cash Flow	-50.00K	-50.00K	-50.00K	-50.00K	50.00K	-	-
Financing Cash Flow	400.80K	7.85M	5.13M	3.73M	11.63M	346.90K	-2.94K
Capital Expenditure	0	0	3	4	5.06M	3	4.19M
Free Cash Flow	-58.82K	-1.05M	-3.36M	-3.30M	-5.06M	-5.70M	-
FCF to OCF	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-

Earnings

Report Date	Jun 9, 2021	Aug 26, 2021	Feb 22, 2022	Aug 23, 2022	Feb 27, 2023	Feb 11, 2025	Aug 28, 2025
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Actual	-0.01	-0.01	-0.02	-0.03	-0.02	-0.01	-0.05
Surprise	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap16.70M

Enterprise Value9.69M

Trailing P/E0.00

Forward P/E0.00

Price / Sales3.04

Price / Book2.72

EPS-0.01

Book Value0.046

Revenue (TTM)5.48M

Gross Profit (TTM)5.48M

Profit Margin-24.90%

Operating Margin48.03%

Return on Equity-20.78%

Return on Assets-11.23%

Shares Outstanding128.46M

Shares Float95.55M

Beta0.78

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%